Edgewise Therapeutics Sees Large Bullish Options Bet Following Asset Sale

Edgewise Therapeutics (NASDAQ: EWTX) was the focus of unusually heavy and one-sided options activity on Friday, with one large trader executing a maneuver that bets on the stock rising to new highs within the next four weeks.

Details of the Trade

According to an analysis by Investing.com, a trader executed a diagonal spread involving 6,000 contracts. The transaction appeared to be a classic "roll-up" maneuver, which involves closing a profitable position to open a new one with a higher strike price and later expiration date.

The specific legs of the trade were:

• Closing (selling) 6,000 contracts of the September 18, 2026, $45 strike call options. With EWTX trading around $46.12, these contracts were in-the-money as they expired.
• Opening (buying) 6,000 contracts of the October 16, 2026, $50 strike call options.

This trade effectively locks in gains from the expiring position while repositioning for further upside. The $50 strike implies a target for the stock to rally approximately 8.4% from its current price, pushing it past its 52-week high of $48.51. The low prior open interest in the October $50 calls indicates this is a new, conviction-driven bet, not the adjustment of an existing hedge.

Ad

Market Signals and Context

The options flow was overwhelmingly bullish, with 6,115 calls trading hands compared to just a single put contract, Investing.com reported. Volatility metrics also provided insight, with overall 3-month implied volatility falling while the demand for calls relative to puts (upside skew) increased. This combination often suggests strategic positioning by informed participants rather than broad speculative panic.

The activity comes after a transformational event for Edgewise. The company recently completed the sale of its muscular dystrophy business to Servier for up to $2.65 billion, including $1.55 billion upfront. This provides a massive cash infusion for a company with a market capitalization of approximately $5 billion, significantly de-risking its balance sheet. The stock has seen a powerful rally over the past year, gaining 197%.

Investor Implications

While the options trade signals strong bullish sentiment from at least one market participant, investors also face a mixed fundamental picture. The recent cash injection is a clear positive for the company's financial stability. However, some valuation models flag the stock as overvalued after its significant run-up, and several analysts have revised earnings estimates downward, according to Investing.com. The company remains unprofitable, and the new $50 call position could expire worthless if the stock's momentum stalls.